Literature DB >> 27093985

[Expression of microRNA-191 in T lymphoblastic leukemia/lymphoma and its underlying mechanism].

Jinghang Zhang1, Xaioyu Yang, Min Li, Xin Huang, Cuiling Liu, Zifen Gao.   

Abstract

OBJECTIVE: To evaluate the correlation between MicroRNA-191 (miR-191) and T lymphoblastic leukemia/lymphoma (T-ALL/LBL) to probe its underlying molecular mechanism.
METHODS: The expression of miR-191 was examined by real-time PCR (RT-PCR) in 20 T-ALL/LBL tissue samples and 20 lymphoid reactive hyperplasia (LRH) tissue samples. The correlation between miR-191 and the clinicopathological feature of T-ALL/LBL was analyzed. Antisense miR-191 lentiviral vectors was constructed and transfected into T-ALL/LBL Jukat cells. After transfection, the expression of miR-191 was examined by RT-PCR. The cell activity was evaluated by CCK-8 asssy. The cell cycle and apoptosis were determined by flow cytometry.
RESULTS: Compared with LRH samples, the results of RT-PCR showed significant upregulation of miR-191 in 20 T-ALL/LBL tissue samples (1.875±0.079 vs 1.000, P<0.05). The expression level of miR-191 was negatively associated with prognosis. Compared with LV-NC-GFP and control groups, the expression of miR-191 significantly decreased after transfection of antisense miR-191 lentiviral vectors (0.578±0.012 vs 1.011±0.053 and 1.000, P<0.05), the percentages of apoptotic cells and the cell in G0/G1 phase significantly increased (P<0.05).
CONCLUSIONS: miR-191 might play a significant role in the development of T-ALL/LBL, implicating a new target for therapy.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27093985     DOI: 10.3760/cma.j.issn.0253-2727.2016.04.003

Source DB:  PubMed          Journal:  Zhonghua Xue Ye Xue Za Zhi        ISSN: 0253-2727


  1 in total

1.  [Detection of promoter and 3' UTR mutation in A20 gene of a case with T cell lymphoma cell leukemia].

Authors:  L L Zhou; G X Luo; L H Zhu; Q Wei; Y Q Wei; R Feng; Y Q Li
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2018-10-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.